Newer influenza antivirals, biotherapeutics and combinations

Influenza and other Respiratory Viruses

Volumn 7, Issue 1 SUPPL.1, 2013, Pages 63-75

  Hayden, Frederick G ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Antibodies; Antivirals; Combinations; Immunomodulators; Influenza; Neuraminidase inhibitors

Indexed keywords

6' SIALYL N ACETYLLACTOSAMINE; A 315675; AMANTADINE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; APROTININ; ARBIDOL; CARRAGEENAN; CYANOVIRIN N; DAS 181; FAVIPIRAVIR; FLUFIRVITIDE; GALECTIN 1; LANINAMIVIR; NITAZOXANIDE; NUCLEOZIN; OSELTAMIVIR; PENTRAXIN 3; PERAMIVIR; PLACEBO; RADAVIRSEN; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; TARIBAVIRIN; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; INFLUENZA; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIBODIES; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA, HUMAN; INJECTIONS, INTRAVENOUS; NEURAMINIDASE; ORTHOMYXOVIRIDAE;

EID: 84871825128     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12045     Document Type: Review

References (184)

1. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 2006; 71:372-378.
2. Ong AK, Hayden FG, John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181-190.
3. Fischer W, Hayden F. Chapter 18. Antivirals for influenza: novel agents and approaches; in Georgiev V, Western K, McGowan J, (eds): National Institute of Allergy and Infectious Diseases, NIH. Totowa NJ: Frontiers in Research Humana Press; 2008:179-192.
4. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48(Suppl 1):S3-S13.
5. Hayden FG. Influenza antivirals: challenges and future directions. Influenza Other Respir Viruses 2011; 5(Suppl. 1):20-26.
6. Krug RM, Aramini JM. Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci 2009; 30:269-277.
7. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008; 78:91-102.
8. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007; 13:3531-3542.
9. Saladino R, Barontini M, Crucianelli M, Nencioni L, Sgarbanti R, Palamara AT. Current advances in anti-influenza therapy. Curr Med Chem 2010; 17:2101-2140.
10. Boltz DA, Aldridge Jr. Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70:1349-1362.
11. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011; 1:563-573.
12. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol Chem 2011; 392:837-847.
13. Hayden FG. Antiviral resistance in influenza viruses: clinical and epidemiological aspects. in: Mayers DL, (ed.): Antimicrobial Drug Resistance. New York, New York: Humana Press; 2009: 1011-1033.
14. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 1:6-10.
15. Hurt AC, Chotpitayasunondh T, Cox NJ et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2011; 12:240-248.
16. NIAID Influenza Antiviral Development Workshop: New Generation. Available from: http://www.niaid.nih.gov/topics/Flu/Documents/fluantiviral09.pdf (Accessed on 26 March 2009).
17. NIAID 2011 Influenza Antiviral Research Pipeline Workshop. Available from: http://www.niaid.nih.gov/about/organization/dmid/meetings/Documents/fluantiviralwkshop2011.pdf (Accessed on 23 March 2011).
18. Guidance for industry influenza: developing drugs for treatment and/or prophylaxis. Available from: http://www.fda.gov/Drugs/guidanceComplianceRegulatoryInformation/Guidances/default.htm (Acce-ssed on 1 April 2011).
19. Ison MG, MD dJ, Gilligan KJ et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-1662.
20. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-1719. (See Supplementary Materials)
21. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53:186-192.
22. Abed Y, Simon P, Boivin G. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob Agents Chemother 2010; 54:2819-2822.
23. Renaud C, Pergam SA, Polyak C et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010; 12:513-517.
24. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-1255.
25. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568-4574.
26. Kohno S, Yen MY, Cheong HJ et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267-5276.
27. Ison M, Hui D, Flynt A, Collis P, Alexander J, Hernandez E. No evidence of resistance in influenza viruses after 5-day IV peramivir therapy in hospitalized patients. ICAAC 2011, V-1541. 2011.
28. Kohno S, Kida H, Mizuguchi M et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-2812.
29. Hernandez JE, Adiga R, Armstrong R et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
30. Fraaij PL, van der Vries E, Beersma MF et al. Evaluation of the anti-viral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011; 204:777-782.
31. Gaur AH, Bagga B, Barman S et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362:88-89.
32. Dulek DE, Williams JV, Creech CB et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50:1493-1496.
33. Yates PJ, Man CY, Zhao H. Interim virological analysis of a prospective single arm phase II study of intravenous zanamivir for the treatment of hospitalized patients with influenza A/H1N1 2009 infection [abstract P-160]. In: Program and abstracts of the International Society for Influenza and other Respiratory Virus Diseases Hong Kong SAR, China: Options for the Control of Influenza VII, 2010:139. Options for the Control of Influenza VII Abstract Book. 9-3-0010.
34. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 2010; 54:1256-1264.
35. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 2010; 50:1319-1329.
36. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575-2582.
37. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167-1175.
38. Macdonald SJ, Watson KG, Cameron R et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother 2004; 48:4542-4549.
39. Macdonald SJ, Cameron R, Demaine DA et al. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 2005; 48:2964-2971.
40. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-1479.
41. Triana-Baltzer GB, Sanders RL, Hedlund M et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother 2011; 66:15-28.
42. Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196:1493-1499.
43. Triana-Baltzer GB, Gubareva LV, Nicholls JM et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009; 4:e7788.
44. Moscona A, Porotto M, Palmer S et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 2010; 202:234-241.
45. Chen YB, Driscoll JP, McAfee SL et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis 2011; 53:e77-e80.
46. Guzman-Suarez BB, Buckley MW, Gilmore ET et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis 2012. doi: 10.1111/j.1399-3062.2012.00718.x.
47. Moss R, Steigbigel R, Wurtman D, Hansen C, Tranel K. A Phase 2A dose-ranging clinical trial of DAS181 for treatment of influenza in healthy adults. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstract V-4052. 9-17-2011.
48. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 2010; 54:2517-2524.
49. Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 2010; 107:882-887.
50. Furuta Y, Takahashi K, Shiraki K et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82:95-102.
51. Smee DF, Hurst BL, Wong MH et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010; 54:126-133.
52. Kobayashi O, Kashiwagi S, Iwamoto A. Clinical effectiveness and safety of favipiravir, a novel anti-influenza drug with a selective inhibition activity against viral RNA polymerase. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, V-405. 9-17-2011.
53. Rossignol JF, La FS, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284:29798-29808.
54. Rossignol JF, Samudrals S, Hoppers M, Haffizulla J. A randomized, double-blind, placebo (PCB) controlled study of nitazoxanide (NTZ) in adults and adolescents with acute uncomplicated influenza. Presented at the IDSA Annual Meeting, Boston. LB-35. 10-22-2011.
55. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
56. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1451.
57. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-456.
58. Friesen RH, Koudstaal W, Koldijk MH et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010; 5:e9106.
59. Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-273.
60. Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251.
61. Simmons CP, Bernasconi NL, Suguitan AL et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
62. Throsby M, van denBE, Jongeneelen M et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:e3942.
63. Ekiert DC, Friesen RH, Bhabha G et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843-850.
64. Corti D, Voss J, Gamblin SJ et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-856.
65. Wang R, Song A, Levin J et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008; 80:168-177.
66. Grandea AG III, Olsen OA, Cox TC et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 2010; 107:12658-12663.
67. El BK, Descamps F, De FM et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011; 186:1022-1031.
68. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59.
69. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181:4168-4176.
70. Fleishman SJ, Whitehead TA, Ekiert DC et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 2011; 332:816-821.
71. Whitehead TA, Chevalier A, Song Y et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol 2012; 30:543-548.
72. Badani H, Garry R, Wilson R, Wimley C. Mechanism and action of flufirvitide, a peptide inhibitor of influenza virus infection. Biophysical 2011; 100:216a.
73. Autoimmune Technologies. LLC 12 A.D. August 3. http://autoimmune.com/Flufirvitide.html
74. Lavrov SV, Eremkina EI, Orlova TG, Galegov GA, Soloviev VD, Zhdanov VM. Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine. Nature 1968; 217:856-857.
75. Hayden FG, Schlepushkin AN, Pushkarskaya NL. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984; 25:53-57.
76. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70:121-131.
77. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007; 12:363-370.
78. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009; 53:2120-2128.
79. Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 2006; 17:185-192.
80. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008; 52:3889-3897.
81. Nguyen JT, Hoopes JD, Le MH et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5:e9332.
82. Smee DF, Hurst BL, Wong MH et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 2010; 88:38-44.
83. Atiee G, Lasseter K, Baughman S et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol 2011; 52:1410-1419.
84. Morrison D, Roy S, Rayner C et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One 2007; 2:e1305.
85. Pukrittayakamee S, Jittamala P, Stepniewska K et al. An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy thai adults. Antimicrob Agents Chemother 2011; 55:4050-4057.
86. Ison MG, Gnann JW Jr, Nagy-Agren S et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190.
87. Duval X, van derWS, Blanchon T et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
88. Nguyen JT, Hoopes JD, Smee DF et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53:4115-4126.
89. Hoopes JD, Driebe EM, Kelley E et al. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 2011; 6:e29778.
90. Nguyen JT, Smee DF, Barnard DL et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 2012; 7:e31006.
91. Kim WY, Young SG, Huh JW et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011; 55:5703-5709.
92. Walsh KB, Teijaro JR, Wilker PR et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A 2011; 108:12018-12023.
93. Zhou H, Jin M, Yu Z et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res 2007; 76:186-193.
94. Devincenzo JP. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir Ther 2012;17(1 Pt B):213-225.
95. Iversen PL, Mourich DV, Voss T. AVI-7100 is effective in oseltamivir resistant H1N1 infected ferrets. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago 9-17-2011, Abstract F1-13725a.
96. Mazur I, Wurzer WJ, Ehrhardt C et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 2007; 9:1683-1694.
97. Eyers S, Weatherall M, Shirtcliffe P, Perrin K, Beasley R. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J R Soc Med 2010; 103:403-411.
98. Hao L, Sakurai A, Watanabe T et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008; 454:890-893.
99. Karlas A, Machuy N, Shin Y et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010; 463:818-822.
100. Brass AL, Huang IC, Benita Y et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139:1243-1254.
101. Josset L, Textoris J, Loriod B et al. Gene expression signature-based screening identifies new broadly effective influenza A antivirals. PLoS One 2010; 5:pii:e13169.
102. Stertz S, Shaw ML. Uncovering the global host cell requirements for influenza virus replication via RNAi screening. Microbes Infect 2011; 13:516-525.
103. Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev Med Virol 2011; 21:358-369.
104. Smith SB, Dampier W, Tozeren A, Brown JR, Magid-Slav M. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS One 2012; 7:e33174.
105. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3:129-142.
106. Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One 2009; 4:e4176.
107. Howard WA, Peiris M, Hayden FG. Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA. Influenza Other Respi Viruses 2011; 5:453-475.
108. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done?. Lancet Infect Dis 2008; 8:571-576.
109. Vandermeer ML, Thomas AR, Kamimoto L et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205:13-19.
110. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011; 342:d1642.
111. Brett SJ, Myles P, Lim WS et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 2011; 6:e18120.
112. Makris D, Manoulakas E, Komnos A et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 2011; 39:2440-2446.
113. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis 2010; 10:256.
114. Martin-Loeches I, Lisboa T, Rhodes A et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37:272-283.
115. Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR III. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16:971-973.
116. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-1206.
117. Kim SH, Hong SB, Yun SC et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183:1207-1214.
118. Baron S, ISAACS A. Absence of interferon in lungs fom fatal cases of influenza. Br Med J 1962; 1:18-20.
119. Agrati C, Gioia C, Lalle E et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 2010; 202:681-689.
120. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 2006; 193:765-772.
121. Abed Y, Nehme B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 2008; 77:163-166.
122. Zhirnov OP, Klenk HD, Wright PF. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 2011; 92:27-36.
123. Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. A novel family of peptides with potent activity against influenza A viruses. J Gen Virol 2012;93(Pt 5):980-986.
124. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 2006; 80:11960-11967.
125. Shi L, Xiong H, He J et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007; 152:1447-1455.
126. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15:997-1005.
127. Smee DF, Bailey KW, Wong MH et al. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 2008; 80:266-271.
128. Leibbrandt A, Meier C, Konig-Schuster M et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One 2010; 5:e14320.
129. Reading PC, Bozza S, Gilbertson B et al. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol 2008; 180:3391-3398.
130. Gambaryan AS, Boravleva EY, Matrosovich TY et al. Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by influenza virus. Antiviral Res 2005; 68:116-123.
131. Droebner K, Ehrhardt C, Poetter A, Ludwig S, Planz O. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral Res 2007; 76:1-10.
132. Mei-Lin Yang M-L, Chen Y-H, Wang S-W et al. Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. J Virology 2011; 85:10010-10020.
133. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005; 68:10-17.
134. Zhang T, Zhao PS, Zhang W et al. Antisense oligonucleotide inhibits avian influenza virus H5N1 replication by single chain antibody delivery system. Vaccine 2011; 29:1558-1564.
135. Mizuta T, Fujiwara M, Abe T et al. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. Biochem Biophys Res Commun 2000; 279:158-161.
136. Su CY, Cheng TJ, Lin MI et al. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 2010; 107:19151-19156.
137. Kao RY, Yang D, Lau LS et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010; 28:600-605.
138. Zhang T, Wang TC, Zhao PS et al. Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1. Int Immunopharmacol 2011; 11:2057-2061.
139. Szretter KJ, Gangappa S, Belser JA et al. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 2009; 83:5825-5834.
140. Kugel D, Kochs G, Obojes K et al. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 2009; 83:3843-3851.
141. Weiss ID, Wald O, Wald H et al. IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J Interferon Cytokine Res 2010; 30:439-449.
142. Xu C, Song X, Fu L et al. Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus. Viral Immunol 2011; 24:369-374.
143. Van HN, Belser JA, Szretter KJ et al. Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol 2009; 83:2851-2861.
144. Wong JP, Christopher ME, Viswanathan S et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009; 27:3481-3483.
145. Wong JP, Christopher ME, Salazar AM, Dale RM, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007; 25:3175-3178.
146. Ranjan P, Jayashankar L, Deyde V et al. 5′PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication. Virol J 2010; 7:102.
147. Hava DL, Griel LC, DeHaan WH, Hubeau C, Kenyon J. Inhaled cationic airway lining modulator (iCALM) therapy, A novel aerosol treatment for respiratory infections reduces clinical symptoms and transmission of influenza A infection. Am J Respir Crit Care Med 2010; 181:A6846.
148. Donovan BW, Reuter JD, Cao Z, Myc A, Johnson KJ, Baker Jr. Jr. Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions. Antivir Chem Chemother 2000; 11:41-49.
149. Motard J, Rouxel R, Paun A, Von Messling V, Bisaillon M, Perreault JP. A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease. PLoS One 2011; 6:e27327.
150. Dimmock NJ, Dove BK, Meng B et al. Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Research 2012; http://dx.doi.org/10.1016/j.antiviral.2012.09.017.
151. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 2003; 36:290-294.
152. Xu T, Qiao J, Zhao L et al. Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice. Eur Respir J 2009; 33:852-860.
153. Radigan KA, Urich D, Misharin AV et al. The effect of rosuvastatin in a murine model of influenza A infection. PLoS One 2012; 7:e35788.
154. Liu Z, Guo Z, Wang G et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 2009; 38:215-223.
155. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51:2965-2968.
156. Aldridge Jr. Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009; 106:5306-5311.
157. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza and Other Respiratory Viruses 2010; 4:307-311.
158. Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol 2011; 186:508-515.
159. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 2008; 105:8091-8096.
160. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 2010; 5:e11610.
161. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 2007; 20:349-354.
162. Lai KY, Ng WY, Osburga ChanPK, Wong KF, Cheng F. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 2010; 152:687-688.
163. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respi Viruses 2007; 1:189-192.
164. Paton NI, Lee L, Xu Y et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011; 11:677-683.
165. Sato K, Suga M, Akaike T et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 1998;157(3 Pt 1):853-857.
166. Hu Y, Jin Y, Han D et al. Mast cell-induced lung injury in mice infected with H5N1 influenza virus. J Virol 2012; 86:3347-3356.
167. Tu W, Zheng J, Liu Y et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J Exp Med 2011; 208:1511-1522.
168. Akaike T, Ando M, Oda T et al. Dependence on O2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Invest 1990; 85:739-745.
169. Grattendick K, Lefkowitz DL, Lefkowitz SS. Inhibition of influenza virus replication by cocaine. Int J Immunopharmacol 2000; 22:105-111.
170. Hammerbeck DM, Burleson GR, Schuller CJ et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res 2007; 73:1-11.
171. Izumo T, Maekawa T, Ida M et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus infection in mice. Int Immunopharmacol 2010; 10:1101-1106.
172. Kobayashi N, Saito T, Uematsu T et al. Oral administration of heat-killed Lactobacillus pentosus strain b240 augments protection against influenza virus infection in mice. Int Immunopharmacol 2011; 11:199-203.
173. Maeda N, Nakamura R, Hirose Y et al. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int Immunopharmacol 2009; 9:1122-1125.
174. Ball MA, Utsunomiya T, Ikemoto K, Kobayashi M, Pollard RB, Suzuki F. The antiviral effect of keishi-ni-eppi-ichi-to, a traditional Chinese herbal medicine, on influenza A2(H2N2) virus infection in mice. Experientia 1994; 50:774-779.
175. Wang C, Cao B, Liu QQ et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med 2011; 155:217-225.
176. Darwish I, Miller C, Kain KC, Liles WC. Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza. Int J Med Sci 2012; 9:157-162.
177. Fusco D, Liu X, Savage C et al. Echinacea purpurea aerial extract alters course of influenza infection in mice. Vaccine 2010; 28:3956-3962.
178. Kosai K, Seki M, Yanagihara K et al. Gabexate mesilate suppresses influenza pneumonia in mice through inhibition of cytokines. J Int Med Res 2008; 36:322-328.
179. Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial. BMC Complement Altern Med 2011; 11:15.
180. Ichinohe T, Nagata N, Strong P et al. Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. J Med Virol 2007; 79:811-819.
181. Kim Y, Narayanan S, Chang KO. Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res 2010; 88:227-235.
182. Buchweitz JP, Karmaus PW, Harkema JR, Williams KJ, Kaminski NE. Modulation of airway responses to influenza A/PR/8/34 by Delta9-tetrahydrocannabinol in C57BL/6 mice. J Pharmacol Exp Ther 2007; 323:675-683.
183. Palamara AT, Nencioni L, Aquilano K et al. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 2005; 191:1719-1729.
184. London NR, Zhu W, Bozza FA et al. Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza Science. Translational Med 2010; 2(23):23ra19.